Solubility and stability enhancement of atorvastatin by cyclodextrin complexation

PDA Journal of Pharmaceutical Science and Technology

Volumn 63, Issue 3, 2009, Pages 217-225

  Palem, Chlnna Reddy ^a   Patel, Shweta ^a   Pokharkar, Varsha B ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

cyclodextrin; Atorvastatin calcium; Dissolution rate; Freeze drying; Kneading; Solubility

Indexed keywords

ATORVASTATIN; BETA CYCLODEXTRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; INFRARED SPECTROSCOPY; STOICHIOMETRY; TABLET PROPERTY; X RAY POWDER DIFFRACTION;

BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; HEPTANOIC ACIDS; HYDROGEN-ION CONCENTRATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 73449145294     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Loftsson T; Brewster, M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilisation and stabilization. J. Pharm. Sci. 1996, 85 (10), 1017-1025.
2. Shyam, S.; Bhaskar, C. Cyclodextrins: Application in different routes of drug administration. Acta Pharm. 2001, 55, 139-156.
3. Martin E. M.; Del V. Cyclodextrins and their uses: A review. Process Biochem. 2004, 39 (9), 1033-1046.
4. Loftsson, T.; Fee, O. R. Cyclodextrins in solid dosage forms. Pharm Tech. 2003, 176-180.
5. Viega, F.; Fernandez, C.; Maincent, P. Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug. Dev. Ind. Pharm. 2001, 27 (6), 523-532.
6. Kerc, J.; Salobir, M.; Bavec, S. Atorvastatin Calcium in a Pharmaceutical Form Composition Thereof and Pharmaceutical Formulation Comprising Atorvastatin Calcium. U.S. Patent 7,030,151 B2, April 18, 2006.
7. Black, A. E.; Michael, W. S.; Roger, N. H. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Met. Dis. 1998, 26 (8), 755-763.
8. Kearny, A. S.; Crawford, L. F.; Mehta, S. C.; Radebaugh, G. W. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxy acid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm. Res. 1993, 10 (10), 1461-1465.
9. Higuchi, T.; Connors, K. A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4, 117-212.
10. Saetern, A. M.; Nguyen, N. B.; Bauer-Brandl, A.; Brandi, M. Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on solubility of camptothecin. Int. J. Pharm. 2004, 284 (1-2), 61-68.
11. Sydyka, E.; Esra, S.; Aktas, L. E.; Ersoy, L.; Ficicioglu, S. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. J. Pharm. Biomed. Anal. 2003, 33 (5), 1017-1023.
12. Zingone, G.; Rubessa, F. Preformulation study of the inclusion complex warfarin- β-cyclodextrin. Int. J. Pharm. 2005, 291 (1-2), 3-10.
13. Mukne, A. P.; Nagarsenker, M. S. Triamterene β-cyclodextrin systems: Preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2004, 5 (1), E19.
14. Wen, X.; Tan, F.; Jing, Z.; Liu, Z. Preparation and study the 1:2 inclusion complex of Carvedilol with β-cyclodextrin. J. Pharm. Biomed. Anal. 2004, 34 (3), 517-523.
15. Nalluri, B. N.; Chowdhary, K. P. R.; Murthy, K. V.; Hayman, A. R.; Becket, G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech 2003, 4(1), E2.
16. Aly, A. M.; Qato, M. K.; Ahmad, M. O. Enhancement of the dissolution rate and bioavailability of glipizide through cyclodextrin inclusion complex. Pharm. Tech. 2003, 27 (6), 54-62.
17. Ghorab, M. M.; Abdel-Salam, H. M.; El-Sayad, M. A.; Mekhel, M. M. Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech 2004, 5 (4), E59.
18. Jacobsen, W.; Kuhn, W. Lactonization is the critical step in the disposition of the 3-hydroxy 3-methyl glutaryl CoA reductase inhibitor atorvastatin. Drug Met. Dis. 2000, 28, 1369-1378.
19. Capello, B.; Carmignani, C.; Iervolini, M.; Immacolata La Rotonda, M.; Fabrizio Saettone, M. Solubilization of tropicamide by hydroxypropyl-β- cyclodextrin and water-soluble polymers: in vitro/in vivo studies. Int. J. Pharm. 2004, 213 (1-2), 75-81.
20. Reddy, M. N.; Rehana, T.; Ramakrishna, S.; Chowdary, K. P.; Diwan, P. V. β-cyclodextrin complexes of Celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS J. 2004, 6 (1), 68-76.
21. Baboota, S.; Agrawal, S. P. Formulation of meloxicam cyclodextrin complexes incorporated tablets. The Indian Pharmacist 2005, 4 (35), 62-66.
22. Jambhekar, S.; Casella, R. The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, hydroxyethyl β-cyclodextrin, and hydroxypropyl β-cyclodextrin complexes. Int. J. Pharm. 2004, 270, 149-166.